Wamkelekile ukuba uze kumzi-mveliso wethu ukuze uthenge ukuthengisa kwangoku, ixabiso eliphantsi, kunye nomgangatho ophezulu we-4-Bromochlorobenzene CAS 106-39-8. Iikristale ze-acicular zivela etywaleni. Indawo yokunyibilika yi-68 ° C, iqondo lokubila yi-196 ° C. .
Njengomvelisi wobuchwephesha, singathanda ukukunika iQuinen CAS 130-95-0.Iquinine, ekwaziwa njenge-cinchona cream kunye ne-cinchona alkaloid, yeyona alkaloid kwixolo lomthi we-cinchona kunye nezihlobo zayo kusapho lwe-rubiaceae. Ixolo leCinchona liqulethe iintlobo ezingaphezu kwama-20 zealkaloids. Ukongeza kwi-quinine, i-quinidine, i-cinchona kunye ne-cinchona ineempembelelo ze-antimalarial.
Okwangoku, i-3-Indoleformic acid CAS 771-50-6 isetyenziswa njenge-pharmaceutical intermediate ye-synthesis ye-tropisetron kunye ne-antiviral drug. Ubume be-3-indolecarboxylic acid kwishishini lokuvelisa amayeza liba libaluleke ngakumbi.
I-2-Aminoethylmethylsulfone hydrochloride CAS 104458-24-4 isitokhwe esimiyo, ukuhanjiswa ngokukhawuleza, Iminyaka yamava okuvelisa kunye nokulawula umgangatho ongqongqo. Njengomvelisi wengcali, singathanda ukukunika umgangatho ophezulu we-2-Aminoethylmethylsulfone hydrochloride CAS 104458-24-4.I-COA, i-MSDS, i-TDS, njl. ye-2-Aminoethylmethylsulfone hydrochloride inokubonelelwa.
I-4-Chlorophenylacetic acid umsebenzi. Njengobuchwephesha obuphezulu obuphezulu be-4-Chlorophenylacetic acid CAS 1878-66-6 yokwenza, unokuqiniseka ukuba uthenge i-4-Chlorophenylacetic acid CAS 1878-66-6 kumzi-mveliso wethu kwaye siya kukubonelela ngeyona nkonzo intle emva kokuthengisa kunye nokuhanjiswa ngexesha. .I-4-Chlorophenylacetic acid Isetyenziswe njenge-pharmaceutical intermediate.
Unokuqiniseka ukuba uthenge i-N- (2-Amino-4,6-dichloro-5-pyrimidinyl) formamide CAS 171887-03-9 kwifektri yethu. I-CAS 171887-03-9 yindawo ephakathi ebalulekileyo ye-abacavir. I-Abacavir lichiza elitsha lokulwa ne-AIDS, elichiza elitsha le-carbocycli2 '-deoxyguanosine nucleoside. I-bioavailability yomlomo iphezulu, kwaye kulula ukungena kwi-CNS Chemicalbook system. Ichiza lilungiselelo le-nucleoside reverse transcriptase elivela kuGlaxo Wilcome elavunywa ukuba lingenwe kwimarike ngenkqubo ye-FDA yokuvunywa ngokukhawuleza ngoDisemba 1998. Ngo-Epreli ka-2004, ichiza lamkelwa yi-FDA lolosulelo oluchasene ne-HIV.
